AustralieFrV1, PascalFrancis, Curation, bibRecord, 005642

Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer

Identifieur interne : 005642 ( PascalFrancis/Curation ); précédent : 005641; suivant : 005643

Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer

Auteurs : Meagan J. Mcgrath [Australie] ; Lauren C. Binge Absorn Sriratana [Australie] ; HONG WANG [Australie] ; Paul A. Robinson [Australie] ; David Pook [Australie] ; Clare G. Fedele [Australie] ; Susan Brown [Australie] ; Jennifer M. Dyson [Australie] ; Denny L. Cottle [Australie] ; Belinda S. Cowling [Australie, France] ; Birunthi Niranjan [Australie] ; Gail P. Risbridger [Australie] ; Christina A. Mitchell [Australie]

Source :

Cancer research : (Chicago, Ill.) [ 0008-5472 ] ; 2013.

RBID : Pascal:13-0291216

Descripteurs français

Pascal (Inist)
- Transcription, Récepteur hormonal, Récepteur androgène, Résistance, Cancer de la prostate, Castration, Homme, Mâle, Facteur transcription, Protéine FHL2.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Androgen receptor, Castration, Hormonal receptor, Human, Male, Prostate cancer, Resistance, Transcription, Transcription factor.

Abstract

It is now clear that progression from localized prostate cancer to incurable castrate-resistant prostate cancer (CRPC) is driven by continued androgen receptor (AR), signaling independently of androgen. Thus, there remains a strong rationale to suppress AR activity as the single most important therapeutic goal in CRPC treatment. Although the expression of ligand-independent AR splice variants confers resistance to AR-targeted therapy and progression to lethal castrate-resistant cancer, the molecular regulators of AR activity in CRPC remain unclear, in particular those pathways that potentiate the function of mutant AR in CRPC. Here, we identify FHL2 as a novel coactivator of ligand-independent AR variants that are important in CRPC. We show that the nuclear localization of FHL2 and coactivation of the AR is driven by calpain cleavage of the cytoskeletal protein filamin, a pathway that shows differential activation in prostate epithelial versus prostate cancer cell lines. We further identify a novel FHL2-AR-filamin transcription complex, revealing how deregulation of this axis promotes the constitutive, ligand-independent activation of AR variants, which are present in CRPC. Critically, the calpain-cleaved filamin fragment and FHL2 are present in the nucleus only in CRPC and not benign prostate tissue or localized prostate cancer. Thus, our work provides mechanistic insight into the enhanced AR activation, most notably of the recently identified AR variants, including AR-V7 that drives CRPC progression. Furthermore, our results identify the first disease-specific mechanism for deregulation of FHL2 nuclear localization during cancer progression. These results offer general import beyond prostate cancer, given that nuclear FHL2 is characteristic of other human cancers where oncogenic transcription factors that drive disease are activated like the AR in prostate cancer.

A01	`01`	`1`		`@0 0008-5472`
A02	`01`			`@0 CNREA8`
A03		`1`		`@0 Cancer res. : (Chic. Ill.)`
A05				`@2 73`
A06				`@2 16`
A08	`01`	`1`	`ENG`	`@1 Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer`
A11	`01`	`1`		`@1 McGRATH (Meagan J.)`
A11	`02`	`1`		`@1 BINGE ABSORN SRIRATANA (Lauren C.)`
A11	`03`	`1`		`@1 HONG WANG`
A11	`04`	`1`		`@1 ROBINSON (Paul A.)`
A11	`05`	`1`		`@1 POOK (David)`
A11	`06`	`1`		`@1 FEDELE (Clare G.)`
A11	`07`	`1`		`@1 BROWN (Susan)`
A11	`08`	`1`		`@1 DYSON (Jennifer M.)`
A11	`09`	`1`		`@1 COTTLE (Denny L.)`
A11	`10`	`1`		`@1 COWLING (Belinda S.)`
A11	`11`	`1`		`@1 NIRANJAN (Birunthi)`
A11	`12`	`1`		`@1 RISBRIDGER (Gail P.)`
A11	`13`	`1`		`@1 MITCHELL (Christina A.)`
A14	`01`			`@1 Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria @3 AUS @Z 1 aut. @Z 2 aut. @Z 4 aut. @Z 6 aut. @Z 7 aut. @Z 8 aut. @Z 9 aut. @Z 10 aut. @Z 13 aut.`
A14	`02`			`@1 Department of Immunology, Monash University, Clayton Victoria @3 AUS @Z 2 aut.`
A14	`03`			`@1 Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria @3 AUS @Z 3 aut. @Z 5 aut. @Z 11 aut. @Z 12 aut.`
A14	`04`			`@1 Department of Oncology, Southern Health @2 East Bentleigh, Victoria @3 AUS @Z 5 aut.`
A14	`05`			`@1 Melanoma Research Laboratory, Peter MacCallum Cancer Centre @2 East Melbourne, Victoria @3 AUS @Z 6 aut.`
A14	`06`			`@1 Department of Translational Medicine and Neurogenetics, Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC), IIlkirch @2 Strasbourg @3 FRA @Z 10 aut.`
A20				`@1 5066-5079`
A21				`@1 2013`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 5088 @5 354000501927990100`
A44				`@0 0000 @1 © 2013 INIST-CNRS. All rights reserved.`
A45				`@0 48 ref.`
A47	`01`	`1`		`@0 13-0291216`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Cancer research : (Chicago, Ill.)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 It is now clear that progression from localized prostate cancer to incurable castrate-resistant prostate cancer (CRPC) is driven by continued androgen receptor (AR), signaling independently of androgen. Thus, there remains a strong rationale to suppress AR activity as the single most important therapeutic goal in CRPC treatment. Although the expression of ligand-independent AR splice variants confers resistance to AR-targeted therapy and progression to lethal castrate-resistant cancer, the molecular regulators of AR activity in CRPC remain unclear, in particular those pathways that potentiate the function of mutant AR in CRPC. Here, we identify FHL2 as a novel coactivator of ligand-independent AR variants that are important in CRPC. We show that the nuclear localization of FHL2 and coactivation of the AR is driven by calpain cleavage of the cytoskeletal protein filamin, a pathway that shows differential activation in prostate epithelial versus prostate cancer cell lines. We further identify a novel FHL2-AR-filamin transcription complex, revealing how deregulation of this axis promotes the constitutive, ligand-independent activation of AR variants, which are present in CRPC. Critically, the calpain-cleaved filamin fragment and FHL2 are present in the nucleus only in CRPC and not benign prostate tissue or localized prostate cancer. Thus, our work provides mechanistic insight into the enhanced AR activation, most notably of the recently identified AR variants, including AR-V7 that drives CRPC progression. Furthermore, our results identify the first disease-specific mechanism for deregulation of FHL2 nuclear localization during cancer progression. These results offer general import beyond prostate cancer, given that nuclear FHL2 is characteristic of other human cancers where oncogenic transcription factors that drive disease are activated like the AR in prostate cancer.
C02	`01`	`X`		`@0 002B14D02`
C02	`02`	`X`		`@0 002B20B02`
C03	`01`	`X`	`FRE`	`@0 Transcription @5 01`
C03	`01`	`X`	`ENG`	`@0 Transcription @5 01`
C03	`01`	`X`	`SPA`	`@0 Transcripción @5 01`
C03	`02`	`X`	`FRE`	`@0 Récepteur hormonal @5 02`
C03	`02`	`X`	`ENG`	`@0 Hormonal receptor @5 02`
C03	`02`	`X`	`SPA`	`@0 Receptor hormonal @5 02`
C03	`03`	`X`	`FRE`	`@0 Récepteur androgène @5 03`
C03	`03`	`X`	`ENG`	`@0 Androgen receptor @5 03`
C03	`03`	`X`	`SPA`	`@0 Receptor andrógeno @5 03`
C03	`04`	`X`	`FRE`	`@0 Résistance @5 04`
C03	`04`	`X`	`ENG`	`@0 Resistance @5 04`
C03	`04`	`X`	`SPA`	`@0 Resistencia @5 04`
C03	`05`	`X`	`FRE`	`@0 Cancer de la prostate @2 NM @5 05`
C03	`05`	`X`	`ENG`	`@0 Prostate cancer @2 NM @5 05`
C03	`05`	`X`	`SPA`	`@0 Cáncer de la próstata @2 NM @5 05`
C03	`06`	`X`	`FRE`	`@0 Castration @5 06`
C03	`06`	`X`	`ENG`	`@0 Castration @5 06`
C03	`06`	`X`	`SPA`	`@0 Castración @5 06`
C03	`07`	`X`	`FRE`	`@0 Homme @5 07`
C03	`07`	`X`	`ENG`	`@0 Human @5 07`
C03	`07`	`X`	`SPA`	`@0 Hombre @5 07`
C03	`08`	`X`	`FRE`	`@0 Mâle @5 08`
C03	`08`	`X`	`ENG`	`@0 Male @5 08`
C03	`08`	`X`	`SPA`	`@0 Macho @5 08`
C03	`09`	`X`	`FRE`	`@0 Facteur transcription @5 09`
C03	`09`	`X`	`ENG`	`@0 Transcription factor @5 09`
C03	`09`	`X`	`SPA`	`@0 Factor transcripción @5 09`
C03	`10`	`X`	`FRE`	`@0 Protéine FHL2 @4 INC @5 86`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'appareil génital mâle @5 37`
C07	`01`	`X`	`ENG`	`@0 Male genital diseases @5 37`
C07	`01`	`X`	`SPA`	`@0 Aparato genital macho patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil urinaire @5 38`
C07	`02`	`X`	`ENG`	`@0 Urinary system disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato urinario patología @5 38`
C07	`03`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 39`
C07	`03`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 39`
C07	`03`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 39`
C07	`04`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`04`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`04`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`05`	`X`	`FRE`	`@0 Pathologie de la prostate @5 40`
C07	`05`	`X`	`ENG`	`@0 Prostate disease @5 40`
C07	`05`	`X`	`SPA`	`@0 Prostata patología @5 40`
N21				`@1 273`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000845

Links to Exploration step

Pascal:13-0291216

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer</title>
<author><name sortKey="Mcgrath, Meagan J" sort="Mcgrath, Meagan J" uniqKey="Mcgrath M" first="Meagan J." last="Mcgrath">Meagan J. Mcgrath</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Binge Absorn Sriratana, Lauren C" sort="Binge Absorn Sriratana, Lauren C" uniqKey="Binge Absorn Sriratana L" first="Lauren C." last="Binge Absorn Sriratana">Lauren C. Binge Absorn Sriratana</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Immunology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Hong Wang" sort="Hong Wang" uniqKey="Hong Wang" last="Hong Wang">HONG WANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Robinson, Paul A" sort="Robinson, Paul A" uniqKey="Robinson P" first="Paul A." last="Robinson">Paul A. Robinson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Pook, David" sort="Pook, David" uniqKey="Pook D" first="David" last="Pook">David Pook</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Oncology, Southern Health</s1>
<s2>East Bentleigh, Victoria</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Fedele, Clare G" sort="Fedele, Clare G" uniqKey="Fedele C" first="Clare G." last="Fedele">Clare G. Fedele</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Melanoma Research Laboratory, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Brown, Susan" sort="Brown, Susan" uniqKey="Brown S" first="Susan" last="Brown">Susan Brown</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Dyson, Jennifer M" sort="Dyson, Jennifer M" uniqKey="Dyson J" first="Jennifer M." last="Dyson">Jennifer M. Dyson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Cottle, Denny L" sort="Cottle, Denny L" uniqKey="Cottle D" first="Denny L." last="Cottle">Denny L. Cottle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Cowling, Belinda S" sort="Cowling, Belinda S" uniqKey="Cowling B" first="Belinda S." last="Cowling">Belinda S. Cowling</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Translational Medicine and Neurogenetics, Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC), IIlkirch</s1>
<s2>Strasbourg</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Niranjan, Birunthi" sort="Niranjan, Birunthi" uniqKey="Niranjan B" first="Birunthi" last="Niranjan">Birunthi Niranjan</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Risbridger, Gail P" sort="Risbridger, Gail P" uniqKey="Risbridger G" first="Gail P." last="Risbridger">Gail P. Risbridger</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Mitchell, Christina A" sort="Mitchell, Christina A" uniqKey="Mitchell C" first="Christina A." last="Mitchell">Christina A. Mitchell</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">13-0291216</idno>
<date when="2013">2013</date>
<idno type="stanalyst">PASCAL 13-0291216 INIST</idno>
<idno type="RBID">Pascal:13-0291216</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000845</idno>
<idno type="wicri:Area/PascalFrancis/Curation">005642</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer</title>
<author><name sortKey="Mcgrath, Meagan J" sort="Mcgrath, Meagan J" uniqKey="Mcgrath M" first="Meagan J." last="Mcgrath">Meagan J. Mcgrath</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Binge Absorn Sriratana, Lauren C" sort="Binge Absorn Sriratana, Lauren C" uniqKey="Binge Absorn Sriratana L" first="Lauren C." last="Binge Absorn Sriratana">Lauren C. Binge Absorn Sriratana</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Immunology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Hong Wang" sort="Hong Wang" uniqKey="Hong Wang" last="Hong Wang">HONG WANG</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Robinson, Paul A" sort="Robinson, Paul A" uniqKey="Robinson P" first="Paul A." last="Robinson">Paul A. Robinson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Pook, David" sort="Pook, David" uniqKey="Pook D" first="David" last="Pook">David Pook</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Oncology, Southern Health</s1>
<s2>East Bentleigh, Victoria</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Fedele, Clare G" sort="Fedele, Clare G" uniqKey="Fedele C" first="Clare G." last="Fedele">Clare G. Fedele</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Melanoma Research Laboratory, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Brown, Susan" sort="Brown, Susan" uniqKey="Brown S" first="Susan" last="Brown">Susan Brown</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Dyson, Jennifer M" sort="Dyson, Jennifer M" uniqKey="Dyson J" first="Jennifer M." last="Dyson">Jennifer M. Dyson</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Cottle, Denny L" sort="Cottle, Denny L" uniqKey="Cottle D" first="Denny L." last="Cottle">Denny L. Cottle</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Cowling, Belinda S" sort="Cowling, Belinda S" uniqKey="Cowling B" first="Belinda S." last="Cowling">Belinda S. Cowling</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Translational Medicine and Neurogenetics, Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC), IIlkirch</s1>
<s2>Strasbourg</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Niranjan, Birunthi" sort="Niranjan, Birunthi" uniqKey="Niranjan B" first="Birunthi" last="Niranjan">Birunthi Niranjan</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Risbridger, Gail P" sort="Risbridger, Gail P" uniqKey="Risbridger G" first="Gail P." last="Risbridger">Gail P. Risbridger</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Mitchell, Christina A" sort="Mitchell, Christina A" uniqKey="Mitchell C" first="Christina A." last="Mitchell">Christina A. Mitchell</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cancer research : (Chicago, Ill.)</title>
<title level="j" type="abbreviated">Cancer res. : (Chic. Ill.)</title>
<idno type="ISSN">0008-5472</idno>
<imprint><date when="2013">2013</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cancer research : (Chicago, Ill.)</title>
<title level="j" type="abbreviated">Cancer res. : (Chic. Ill.)</title>
<idno type="ISSN">0008-5472</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Androgen receptor</term>
<term>Castration</term>
<term>Hormonal receptor</term>
<term>Human</term>
<term>Male</term>
<term>Prostate cancer</term>
<term>Resistance</term>
<term>Transcription</term>
<term>Transcription factor</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Transcription</term>
<term>Récepteur hormonal</term>
<term>Récepteur androgène</term>
<term>Résistance</term>
<term>Cancer de la prostate</term>
<term>Castration</term>
<term>Homme</term>
<term>Mâle</term>
<term>Facteur transcription</term>
<term>Protéine FHL2</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">It is now clear that progression from localized prostate cancer to incurable castrate-resistant prostate cancer (CRPC) is driven by continued androgen receptor (AR), signaling independently of androgen. Thus, there remains a strong rationale to suppress AR activity as the single most important therapeutic goal in CRPC treatment. Although the expression of ligand-independent AR splice variants confers resistance to AR-targeted therapy and progression to lethal castrate-resistant cancer, the molecular regulators of AR activity in CRPC remain unclear, in particular those pathways that potentiate the function of mutant AR in CRPC. Here, we identify FHL2 as a novel coactivator of ligand-independent AR variants that are important in CRPC. We show that the nuclear localization of FHL2 and coactivation of the AR is driven by calpain cleavage of the cytoskeletal protein filamin, a pathway that shows differential activation in prostate epithelial versus prostate cancer cell lines. We further identify a novel FHL2-AR-filamin transcription complex, revealing how deregulation of this axis promotes the constitutive, ligand-independent activation of AR variants, which are present in CRPC. Critically, the calpain-cleaved filamin fragment and FHL2 are present in the nucleus only in CRPC and not benign prostate tissue or localized prostate cancer. Thus, our work provides mechanistic insight into the enhanced AR activation, most notably of the recently identified AR variants, including AR-V7 that drives CRPC progression. Furthermore, our results identify the first disease-specific mechanism for deregulation of FHL2 nuclear localization during cancer progression. These results offer general import beyond prostate cancer, given that nuclear FHL2 is characteristic of other human cancers where oncogenic transcription factors that drive disease are activated like the AR in prostate cancer.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0008-5472</s0>
</fA01>
<fA02 i1="01"><s0>CNREA8</s0>
</fA02>
<fA03 i2="1"><s0>Cancer res. : (Chic. Ill.)</s0>
</fA03>
<fA05><s2>73</s2>
</fA05>
<fA06><s2>16</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>McGRATH (Meagan J.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BINGE ABSORN SRIRATANA (Lauren C.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HONG WANG</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>ROBINSON (Paul A.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>POOK (David)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FEDELE (Clare G.)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>BROWN (Susan)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>DYSON (Jennifer M.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>COTTLE (Denny L.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>COWLING (Belinda S.)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>NIRANJAN (Birunthi)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>RISBRIDGER (Gail P.)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>MITCHELL (Christina A.)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Biochemistry and Molecular Biol ogy, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Immunology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Prostate and Breast Cancer Research Group, Department of Anatomy and Developmental Biology, Monash University, Clayton Victoria</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>11 aut.</sZ>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Oncology, Southern Health</s1>
<s2>East Bentleigh, Victoria</s2>
<s3>AUS</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Melanoma Research Laboratory, Peter MacCallum Cancer Centre</s1>
<s2>East Melbourne, Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Translational Medicine and Neurogenetics, Institut de Genetique et de Biologie Moleculaire et Cellulaire (IGBMC), IIlkirch</s1>
<s2>Strasbourg</s2>
<s3>FRA</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>5066-5079</s1>
</fA20>
<fA21><s1>2013</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>5088</s2>
<s5>354000501927990100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2013 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>48 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>13-0291216</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Cancer research : (Chicago, Ill.)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>It is now clear that progression from localized prostate cancer to incurable castrate-resistant prostate cancer (CRPC) is driven by continued androgen receptor (AR), signaling independently of androgen. Thus, there remains a strong rationale to suppress AR activity as the single most important therapeutic goal in CRPC treatment. Although the expression of ligand-independent AR splice variants confers resistance to AR-targeted therapy and progression to lethal castrate-resistant cancer, the molecular regulators of AR activity in CRPC remain unclear, in particular those pathways that potentiate the function of mutant AR in CRPC. Here, we identify FHL2 as a novel coactivator of ligand-independent AR variants that are important in CRPC. We show that the nuclear localization of FHL2 and coactivation of the AR is driven by calpain cleavage of the cytoskeletal protein filamin, a pathway that shows differential activation in prostate epithelial versus prostate cancer cell lines. We further identify a novel FHL2-AR-filamin transcription complex, revealing how deregulation of this axis promotes the constitutive, ligand-independent activation of AR variants, which are present in CRPC. Critically, the calpain-cleaved filamin fragment and FHL2 are present in the nucleus only in CRPC and not benign prostate tissue or localized prostate cancer. Thus, our work provides mechanistic insight into the enhanced AR activation, most notably of the recently identified AR variants, including AR-V7 that drives CRPC progression. Furthermore, our results identify the first disease-specific mechanism for deregulation of FHL2 nuclear localization during cancer progression. These results offer general import beyond prostate cancer, given that nuclear FHL2 is characteristic of other human cancers where oncogenic transcription factors that drive disease are activated like the AR in prostate cancer.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B14D02</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B20B02</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Transcription</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Transcription</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Transcripción</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Récepteur hormonal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Hormonal receptor</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Receptor hormonal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Récepteur androgène</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Androgen receptor</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Receptor andrógeno</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Résistance</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Resistance</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Resistencia</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Cancer de la prostate</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Prostate cancer</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cáncer de la próstata</s0>
<s2>NM</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Castration</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Castration</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Castración</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Homme</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Human</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hombre</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Mâle</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Male</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Macho</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Facteur transcription</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Transcription factor</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Factor transcripción</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Protéine FHL2</s0>
<s4>INC</s4>
<s5>86</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'appareil génital mâle</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Male genital diseases</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Aparato genital macho patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil urinaire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Urinary system disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato urinario patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie de la prostate</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Prostate disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Prostata patología</s0>
<s5>40</s5>
</fC07>
<fN21><s1>273</s1>
</fN21>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005642 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 005642 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:13-0291216
   |texte=   Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer

Regulation of the Transcriptional Coactivator FHL2 Licenses Activation of the Androgen Receptor in Castrate-Resistant Prostate Cancer

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri